Little Green Pharma Ltd (ASX: LGP) has shipped its first batch of LGP- branded high-THC Desert Flame cannabis flower products to Poland ..read more

Predictive diagnostics pioneer Proteomics International Laboratories’ (ASX: PIQ) subsidiary OxiDx Pty Ltd has been granted a patent in 19 major European countries for its platform technology to ..read more

ABx Group Limited (ASX:ABX) has appointed highly experienced director Joycelyn Morton as an independent non- executive director, as well as 83%-owned subsidiary ALCORE ..read more

ABx Group Limited (ASX:ABX) has appointed highly experienced director Joycelyn Morton as an independent non- executive director, as well as 83%-owned subsidiary ALCORE ..read more

QEM Limited (ASX: QEM) has partnered with The University of Queensland to produce the first high purity vanadium pentoxide (V2O5) from an industrial waste stream in Australia. V2O5 is the essential ..read more

Little Green Pharma (ASX: LGP) has welcomed historic move of the German Bundestag to vote to legalise cannabis by removing it from the Narcotics List from 1 April 2024. This represents the most ..read more

Little Green Pharma Ltd’s (ASX: LGP) psychedelics focused subsidiary Reset Mind Sciences has launched its clinical trial into the efficacy and safety of psilocybin assisted therapy involving family members for patients with treatment resistant major depressive disorder. The clinical Trial, anticipated to take 12 months to complete, builds on the increasing body of research globally into the use of psilocybin to treat depressive related conditions by incorporating key family members into the preparatory and integration therapy sessions that precede and follow the psilocybin administration sess ..read more

Rapid, point-of-care (POC) diagnostic technology developer Lumos Diagnostics Holdings (ASX:LDX) has signed two new agreements with US based women’s health company, Hologic, Inc. Hologic is a leading innovator and diagnostics service provider in women’s health and has engaged Lumos to develop a next generation version of one of Hologic’s leading on-market women’s health products. The two agreements encompass a Development Agreement and an Intellectual Property (IP) Agreement. Under the Development Agreement Lumos is entitled to receive up to US$4.7 million in payments over an 18-24 month timef ..read more

Commercial-stage regenerative medicine company AVITA Medical (ASX: AVH) has entered into an exclusive multi-year distribution agreement with Stedical Scientific to commercialise PermeaDerm Biosynthetic Wound Matrix in the United States. PermeaDerm is cleared by the Food and Drug Administration as a transparent matrix for use in the treatment of a variety of wound types until healing is achieved. Under the terms of the agreement, AVITA Medical will hold the exclusive rights to market, sell, and distribute PermeaDerm products, including any future enhancements or modifications, within the Unite ..read more

Mental health and select neurological health treatment developer Emyria Limited’s (ASX: EMD) distinguished psychiatry specialist has been granted “Authorised Prescriber” status by the Therapeutic Goods Administration (TGA). The authorisation enables the prescribing of MDMA according to an ethics committee endorsed care model developed by Emyria and within the strict regulatory framework established by the TGA for the treatment of Post-Traumatic Stress Disorder (PTSD). This authorisation demonstrates Emyria’s commitment to evaluating emerging treatments within the strict regulatory framework ..read more